A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis

Gastroenterology

Volumn 106, Issue 6, 1994, Pages 1429-1435

  Sandborn, William J ^a   Tremaine, William J ^a   Schroeder, Kenneth W ^a   Batts, Kenneth P ^b   Lawson, George M ^b   Steiner, Betty L ^a   Harrison, Jay M ^b   Zinsmeister, Alan R ^b  

^a Division of Gastroenterology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBOXYMETHYLCELLULOSE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DRUG VEHICLE; ENEMA; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; SALAZOSULFAPYRIDINE; SORBITOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0028271186     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(94)90394-8     Document Type: Article

References (36)

1. Effect of cyclosporin A on human lymphocyte response in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF
2. Cyclosporin in ulcerative colitis
3. Cyclosporin-induced remission in severe colitis unresponsive to corticosteroid therapy (abstr)
4. Cyclosporin A in acute ulcerative colitis
5. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis
6. Cyclosporine treatment of fulminant colitis
7. Cyclosporin A treatment in inflammatory bowel disease
8. Cyclosporin for the treatment of severe inflammatory bowel disease
9. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis
10. Cyclosporine therapy in inflammatory bowel disease: open-label experience
11. Cyclosporin treatment for severe active ulcerative colitis (letter)
12. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis
13. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation
14. Cyclosporine treatment of severe ulcerative colitis in children
15. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis
16. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids
17. Cyclosporin A in the treatment of severe ulcerative colitis (abstr)
18. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin
19. Cyclosporin A in the treatment of severe, refractory ulcerative colitis: a double blinded placebo controlled trial (abstr)
20. Cyclosporine treatment of inflammatory bowel disease
21. The pharmacokinetics and colonic tissue concentrations of cyclosporine after IV, oral, and enema administration
22. Cyclosporine enemas for treatment of treatment-resistant, mildly to moderately active, left-sided ulcerative colitis
23. Cyclosporin enemas for therapy-resistant ulcerative proctitis
24. Treatment of refractory ulcerative colitis with cyclosporine enemas
25. Treatment of chronic proctosigmoiditis with cyclosporin enemas (letter)
26. Cyclosporin A retention enemas in refractory distal colitis: an open trial (abstr)
27. Medical treatment of refractory distal ulcerative colitis
28. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial
29. Variation between observers in describing mucosal appearances in proctocolitis
30. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study
31. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis
32. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
33. 5-aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis
34. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution
35. Improved chromatography of cyclosporine
36. Cyclosporine: a review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems